Amphiphilic block copolymer nanoparticles have been widely explored for the encapsulation of anti-cancer drug therapeutics to both enhance the biodistribution and reduce toxicity profiles of these potent drug molecules. [1] [2] [3] The discovery of 'living' radical polymerisation techniques, such as reversible addition-fragmentation chain-transfer (RAFT) polymerization, [4] [5] [6] has allowed the efficient preparation of a vast range of amphiphilic block copolymers. These polymers can form polymeric nanoparticles by emulsion-solvent evaporation methods. 7 Introduction of poly(ethylene glycol) (PEG) in their structures 8 allows the formation of stealth polymeric nanoparticles, which further enhance the encapsulated drug efficacy by slowing its rate of clearance by the reticuloendothelial system. 9, 10 Whilst it has been clinically demonstrated that nanoparticles can passively target solid tumours through the enhanced permeability and retention effect, they can be further tailored by functionalizing their exterior with targeting ligands (peptides, carbohydrates or antibodies) to endow them with 'active-targeting' properties, promoting enhanced uptake at the tumour site. 11 To date, different conjugation chemistries have been employed for nanoparticle surface functionalization, including thiol, 12 amine, 13 maleimide and carbodiimide approaches. 14 Given the complexity of the resultant nanoconjugate, there is a need for selective, site-specific and stable conjugation approaches, which will be more amendable to scale-up manufacturing and regulatory standards. 15, 16 One alternative conjugation strategy reported by Wooley et al. involves the incorporation of benzaldehyde groups within the polymer structure. The authors prepared poly(ethylene oxide)-b-poly(4-vinyl benzaldehyde) polymer vesicles with benzaldehyde groups in their vesicular walls, used for cross-linking and functionalization with fluorescein by reductive amination chemistry. 17 Herein, we synthesise a P(OEGMA-st-pFPMA)-b-PDPA amphiphilic block copolymer by RAFT polymerization in ethanol and investigate its ability to generate nanoparticles via single emulsion-solvent evaporation method (Scheme 1). The polymer was designed with a range of functional properties. Firstly, a PEG-based P(OEGMA-st-pFPMA) hydrophilic block was chosen to give improved biocompatibility and 'stealth-like' properties to the nanoparticles to limit opsonisation. 18, 19 Secondly, the PDPA hydrophobic (at 27, 28 show overexpression of this receptor. EGFR can promote cancer cell proliferation, angiogenesis and invasion whilst simultaneously deactivate programmed cell death (apoptosis) and cell specialization. 29 Importantly, EGFR is amendable to antibody binding, with two antibodies, Cetuximab 30 and Panitumumab, 31 used clinically to abrogate EGFR signalling.
Mao et al. previously synthesized P(OEGMA-stpFPMA)-b-PDPA block copolymers in 1,4-dioxane by RAFT polymerization. These were prepared by chain extending a PDPA macromolecular chain transfer agent (macro-CTA) with an OEGMA/pFPMA monomer mixture. 32 However, Prat et al. recently purported that 1,4-dioxane is a 'hazardous' solvent, and should be avoided, while alcohols (i.e. ethanol, methanol) were ranked as 'recommended'. 33 Here, the P(OEGMA-st-pFPMA)-b-PDPA amphiphilic block copolymer was prepared in ethanol. The synthesis was reversed, starting from the shorter P(OEGMA-stpFPMA) block to ensure good blocking efficiency and better pFPMA incorporation in the POEGMA chain that could be confirmed by proton nuclear magnetic resonance (
spectroscopy. 4-Cyano-4-(phenylcarbonothi oylthio)pentanoic acid (CADB) RAFT CTA and 4,4'-azobis(4-cyanovaleric acid) (ACVA) initiator were used to polymerize an OEGMA/pFPMA mixture. The resulting P(OEGMA-st-pFPMA) macro-CTA was chain extended with DPA monomer (Scheme 1).
A combination of 1 H NMR spectroscopy and size exclusion chromatography (SEC) in tetrahydrofuran (THF) confirmed the successful preparation of the macro-CTA. Its 1 H NMR spectrum showed high OEGMA monomer conversion (~92% , Table S1 ) at 4 h, corresponding to an OEGMA mean degree of polymerisation of 23. The conversion was calculated by comparing the area under the monomer methacrylic peaks at 5.58 and 6.14 ppm with that of the polymer/monomer signals at 4.09 ppm. The purified macro-CTA (after methanol dialysis) and the block copolymer were characterized by 1 H NMR spectroscopy and SEC (THF). For the macro-CTA, the presence of the benzaldehyde proton at 10.0 ppm and absence of monomer methacrylic protons in the 1 H NMR spectrum ( Figure S1A ) verified the successful incorporation of the benzaldehyde monomer into the macro-CTA chain. Although an average of 1 pFPMA unit is incorporated in the polymer chains, and therefore a significant fraction of chains do not contain pFPMA, this does not significantly affect the nanoparticle functionalization, which consists of many polymer chains. The SEC data ( Figure 1 and Table S1) indicated that the macro-CTA was polymerized with good control, giving a narrow molecular weight distribution (MWD) with a dispersity (Ð) value of 1.12. The slight shoulder in the chromatogram at higher molecular weights (MWs) was attributed to ethyleneglycol dimethacrylate cross-linker traces present in the OEGMA monomer from its manufacture, causing chain-chain coupling reactions. However, these were not deemed to be significant enough to hinder the block copolymer synthesis. The number average molecular weight (Mn) of 9,600 g.mol -1 obtained for the macro-CTA by SEC was in close agreement with the MW value (10,800 g.mol (Table S1 , entry 1).
The macro-CTA chain extension for the P(OEGMA 23 -stpFPMA1)-b-PDPA235 diblock copolymer formation was performed using 300 molar equivalents of DPA monomer and Table S1 , entry 2) and the presence of the characteristic PDPA isopropyl protons in the 1 H NMR spectrum of the purified diblock copolymer ( Figure S1B ) at 1.04, 2.67 and 3.03 ppm, after the macro-CTA ( Figure S1A ) chain extension, confirmed its successful synthesis. As expected, the SEC chromatogram (Figure 1) , showed a shift to lower retention time as the DPA monomer was polymerized and incorporated into the polymer chain. The SEC data indicated high macro-CTA blocking efficiency and relatively narrow MWD (Ð~1.46, Table S1) for the block copolymer. The difference between its SEC Mn (37,400 g.mol -1 ) and 1 H NMR MW (60,900 g.mol -1 ; Table S1 , entry 2) could be due to the broader MWD (tailing effect in the chromatogram), attributed to interactions between the PDPA side chains and SEC columns, and/or slow initiation for the second block.
Next, the benzaldehyde-functionalized block copolymer was used to produce nanoparticles by a single emulsionsolvent evaporation approach (Scheme 1), used in our previous work for preparation of PLGA and PLGA-PEG nanoparticle formulations. 24, 25, 34 Assessment by dynamic light scattering (DLS) demonstrated that this approach successfully generated nanoparticles with a mean hydrodynamic diameter of ~230 nm ( Figure 2 and Table S2 ). A uniform monodisperse formulation was obtained (low Ð value of 0.047). Size and uniformity was subsequently confirmed by nanoparticle tracking analysis (NTA, Figure S2 ) and scanning electron microscopy (SEM) imaging (Figure 2 ), confirming formation of nanoparticles at neutral pH. A key attribute of the nanoparticle design strategy was their pH responsiveness, to allow rapid release of encapsulated payloads in intracellular endo/lyosomal compartments. A pH decrease, below the PDPA block pKa value (~6.4), protonates its tertiary amine groups, rendering it hydrophilic. This results in nanoparticle collapse and release of encapsulated cargo. To examine the structural integrity of the nanoparticle solutions, their turbidity (450 nm) was examined across a pH range. Nanoparticles appear turbid and strongly scatter visible light. In contrast, unimers, due to their very small size, cannot scatter light as efficiently. The obtained UV-Vis data ( Figure S4 ) showed a gradual increase in transmittance with pH drop, consistent with nanoparticle collapse to unimers, with full collapse appearing by pH 5.7. Next, fluorescent nanoparticles were produced by entrapping rhodamine 6G as a model hydrophobic agent and drug molecule surrogate. Nanoparticles of 263 nm hydrodynamic diameter (DLS , Table S2 ) were prepared as before via addition of rhodamine 6G into the organic phase. Subsequently, a release study was conducted at pH 7.4, 6.5 and pH 5.5, mimicking the release patterns outside the cell, within early and late stage endosomes, respectively. At pH 7.4 and 6.5, a relatively controlled dye release was observed over time ( Figure S5 ), through diffusion from the nanoparticles. At the lower pH (5.5), a significantly faster burst release was observed, indicative of the loss of nanoparticle integrity at this pH, triggering release of the cargo.
Visualization of the fate of these rhodamine 6G loaded nanoparticles in cell-based assays was then carried out. A549 lung epithelial cells are endocytotic and can be used to examine uptake of particulates. 35, 36 Parallel cell cultures in presence or absence of 1 μM bafilomycin were prepared before exposure to rhodamine 6G loaded nanoparticles. Representative micrographs (Figure 3) showed that without bafilomycin pretreatment, rhodamine fluorescence was observed in the cells in a rather diffuse pattern (orange arrows) compared to the punctate staining evidenced in the bafilomycin treated cells (green arrows). Bafilomycin inhibits the acidification of endosomal compartments through its action on V-ATPases. 37 Therefore, the observed punctate staining is suggestive of improved nanoparticle integrity, due to the maintenance of endosomal pH above the PDPA pK a value. These in vitro and cell-based assessments indicate that this block polymer can successfully generate nanoparticles (at neutral pH) that lose integrity and release encapsulated contents at endosomal pH. The biocompatibility of the formulation was next assessed. Nanoparticle solutions (0-0.2 mg/mL) were incubated with A549 cells. CellTiter-Glo assay (48 h) showed no significant alterations in cell viability, suggesting that the particles were well tolerated by the cells (Figure S6 ).
The benzaldehyde functionality of the nanoparticles was used for conjugating an aminooxy-functionalized sdAb targeting EGFR. This approach was chosen as it facilitates a site-specific conjugation, resulting in formation of a stable oxime bond. This has been previously reported to be the linkage of choice for conjugating molecules via carbon-nitrogen double bonds, due to its increased robustness to hydrolysis. 38 The EGFR binding sdAb 7C12 was generated with a unique C-terminal aminooxy functionality. 39, 40 Its characterization was performed by SDS PAGE analysis and electrospray mass spectrometry ( Figure S7 ). Addition of sdAb (100 μg) to nanoparticles (2 mg), followed by 24 h agitation at 4 0 C in the presence of para-phenylenediamine catalyst, resulted in a sdAb conjugation of 5.25 μg/mg polymer. The antibody-functionalized nanoparticles hydrodynamic diameter by DLS was ~263 nm (Table S2) .
A modified ELISA procedure was developed using immobilized EGFR (recombinant human EGFR-Fc chimeric protein) on microtiter plates to ascertain the ability of the sdAb to bind to its cognate receptor after conjugation to the nanoparticles ( Figure 4A ). Rhodamine 6G loaded nanoparticles were used for the detection of nanoparticle binding to the immobilized receptor. Binding was assessed for nude nanoparticles with no sdAb [P(OEGMA23-stpFPMA 1 )-b-PDPA 235 ], used as a control, and targeted nanoparticles with sdAb on their surface (P(OEGMA23-stpFPMA1)-b-PDPA235+anti-EGFR) in the presence (+EGFR) and absence (-EGFR) of EGFR-Fc by fluorescence spectroscopy. A three-fold increase of particle binding to EGFR was observed for anti-EGFR sdAb nanoparticles compared to the control. This indicated that the conjugation procedure had not affected the ability of the sdAb paratope to recognize and bind its cognate epitope on the EGFR protein. In vitro cellular uptake was also investigated. HeLa cells were incubated with nanoparticles for 1 h at 4ºC to allow binding, whilst prohibiting cellular internalization. 41 Cells were washed to remove any unbound nanoparticles before incubation (37ºC, 2 h), enabling the uptake of surfacebound nanoparticles. The expression of EGFR on the surface of HeLa cells was confirmed by fluorescence-activated cell sorting (FACS) analysis, proving that these cells were a suitable model to study nanoparticle-EGFR interactions ( Figure S8 ). The level of nanoparticle uptake was quantified using confocal microscopy ( Figure S9 ). The results highlight that sdAb targeting facilitated enhanced nanoparticle uptake. The antibody-functionalized nanoparticles showed higher uptake than the nude nanoparticles ( Figure 4B ). Here, we have described the synthesis of a novel benzaldehyde-functionalized amphiphilic block copolymer, which was successfully used to prepare pH-responsive nanoparticles. We then show successful site-specific conjugation of aminooxy-functionalized sdAb to facilitate active targeting of these novel nanoparticles. Although further work on the biocompatibility and biodistribution of nanoparticles will be necessary in the future, we envisage similar renal excretion to other methacrylic polymer nanostructures evaluated. 42 In conclusion, this approach provides an ideal strategy for the development of next-generation targeted cancer therapy.
